Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer

Cancer Science
Shi XuJames Chung-Man Ho

Abstract

Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer cases. Small cell lung cancer is characterized by frequent relapse, and current treatments lack tumor specificity. Arginine is a non-essential amino acid for human normal cells but critical to some tumor cells that cannot synthesize arginine. Therefore, arginine deprivation has become a potential therapeutic option for selected tumors. BCT-100 is a pegylated arginase that has documented anticancer activity in arginine auxotrophic tumors, such as melanoma, hepatocellular carcinoma, and acute myeloid leukemia. One of the resistance mechanisms to arginase treatment is overexpression of argininosuccinate synthetase (ASS1) and ornithine transcarbamylase (OTC), two important enzymes in the urea cycle. We selected 9 SCLC and 1 non-small cell lung carcinoma cell lines to determine the growth inhibition effects of BCT-100 and established that cell lines with low expression of ASS1 and OTC are relatively sensitive to BCT-100 treatment. Knocking down OTC in a H841 cell line could potentiate its sensitivity to BCT-100 treatment. Arginine concentration was sharply decreased, accompanied by apoptosis through oxidative stress as well as G1 cell cycle arrest. In ad...Continue Reading

References

Nov 10, 1998·The Biochemical Journal·G Wu, S M Morris
Jun 22, 2006·Expert Opinion on Investigational Drugs·Lynn Feun, Niramol Savaraj
Aug 7, 2012·BMC Cancer·Christina A KousparouAgamemnon A Epenetos
Aug 10, 2012·Current Cancer Drug Targets·Ariel K M ChowRoberta W C Pang
Aug 17, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Thomas H FinkMartin Wolf
Aug 15, 2014·Proceedings of the National Academy of Sciences of the United States of America·Chun A ChangouHsing-Jien Kung
Apr 29, 2015·Cancer Letters·Fuming QiuMeihua Sui
Nov 9, 2015·Applied Biochemistry and Biotechnology·Tahira BatoolMashitah M Yusoff
Dec 17, 2015·Advances in Experimental Medicine and Biology·Lindsey A TorreAhmedin Jemal
Mar 24, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aimee Bence LinRichard P Beckmann
May 4, 2017·Respiratory Research·Sze-Kwan LamJames Chung-Man Ho
May 20, 2017·Oncotarget·Medhi WangpaichitrNiramol Savaraj
Nov 23, 2017·Oncotarget·Anke MaesElke De Bruyne

❮ Previous
Next ❯

Citations

Jun 18, 2020·International Journal of Molecular Sciences·Sai-Fung ChungWai-Hung Lo
Jan 30, 2021·Frontiers in Pharmacology·Ziyu WangDianwen Ju
Sep 25, 2020·International Journal of Biological Macromolecules·Suet-Ying TamYun-Chung Leung

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
Protein Assay
ELISA
transfection
flow cytometry
xenograft
Assay

Software Mentioned

Prism
GraphPad
GelQuantNET

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.